Metabolomic study on urine of chronic inflammation rats treated with Buyang Huanwu Decoction based on UPLC-Q-TOF-MS.
10.19540/j.cnki.cjcmm.20230510.401
- Author:
Xin-Yi YOU
1
;
Li JIANG
2
;
Wen-Feng WANG
1
;
Xia XU
3
;
Shou-Wen ZHANG
4
;
Hong-Ning LIU
1
;
Xiao-Jun YAN
1
;
Peng NIE
1
;
Bing-Tao LI
2
;
Guo-Liang XU
2
Author Information
1. Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Etiopathogenisis, Research Center for Differentiation and Development of Traditional Chinese Medicine Basic Theory, Jiangxi University of Chinese Medicine Nanchang 330004, China.
2. Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Etiopathogenisis, Research Center for Differentiation and Development of Traditional Chinese Medicine Basic Theory, Jiangxi University of Chinese Medicine Nanchang 330004, China Key Laboratory of Pharmacology of Traditional Chinese Medicine in Jiangxi Nanchang 330004, China.
3. Qilu Hospital of Shandong University Dezhou Hospital Dezhou 253000, China.
4. Research Center for Traditional Chinese Medicine Resources and Ethnic Minority Medicine, Jiangxi University of Chinese Medicine Nanchang 330004, China.
- Publication Type:Journal Article
- Keywords:
Buyang Huanwu Decoction;
UPLC-Q-TOF-MS;
chronic inflammation;
metabolic mechanism;
metabolic pathway;
metabolomics
- MeSH:
Rats;
Male;
Animals;
Chromatography, High Pressure Liquid/methods*;
Lipopolysaccharides;
Rats, Sprague-Dawley;
Metabolomics/methods*;
Inflammation/drug therapy*;
Biomarkers/urine*
- From:
China Journal of Chinese Materia Medica
2023;48(19):5345-5355
- CountryChina
- Language:Chinese
-
Abstract:
The study investigated the effect of Buyang Huanwu Decoction(BYHWD) on endogenous biomarkers in the urine of rats with chronic inflammation induced by lipopolysaccharide(LPS) using ultra-high performance liquid chromatography-quadrupole-time-of-flight-mass spectrometry(UPLC-Q-TOF-MS), aiming to elucidate the molecular mechanism underlying the therapeutic effect of BYHWD on chronic inflammation from a metabolomics perspective. Male SD rats were randomly divided into a normal group, a model group, and low-, medium-, and high-dose BYHWD groups(7.5, 15, and 30 g·kg~(-1)). The model group and BYHWD groups received tail intravenous injection of LPS(200 μg·kg~(-1)) on the first day of each week, followed by oral administration of BYHWD once a day for four consecutive weeks. Urine samples were collected at the end of the administration period, and UPLC-Q-TOF-MS was used to analyze the metabolic profiles of the rat urine in each group. Multivariate statistical analysis methods such as principal component analysis(PCA), partial least squares-discriminant analysis(PLS-DA), and orthogonal partial least squares-discriminant analysis(OPLS-DA) were used to analyze the effect of BYHWD on endogenous metabolites. One-way ANOVA and variable importance for the projection(VIP) were used to screen for potential biomarkers related to chronic inflammation. The identified biomarkers were subjected to pathway and enrichment analysis using MetaboAnalyst 5.0. A total of 25 potential biomarkers were screened and identified in the rat urine in this experiment. Compared with the normal group, the model group showed significant increases in the levels of 14 substances(P<0.05) and significant decreases in the levels of 11 substances(P<0.05). BYHWD was able to effectively reverse the trend of most endogenous biomarkers. Compared with the model group, BYHWD significantly down-regulated 13 biomarkers(P<0.05) and up-regulated 10 biomarkers(P<0.05). The metabolic products were mainly related to the biosynthesis of pantothenic acid and coenzyme A, tryptophan metabolism, retinol metabolism, and propionate metabolism. BYHWD has therapeutic effect on chronic inflammation induced by LPS, which may be related to its ability to improve the levels of endogenous metabolites, enhance the body's anti-inflammatory and antioxidant capabilities, and restore normal metabolic activity.
